| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|
Phase N/A 1
2 3 4 Trials | | 0 | 36912151821242730 |
|---|
| | | | |
|---|
| | | | |
|---|
| | | | |
|---|
| VRC07-523LS / National Institute of Allergy and Infectious Diseases, IAVI, TaiMed Biologics | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| PGT121 / Gilead, IAVI | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| BG505 SOSIP 664 gp140 adjuvanted vaccine / GSK, IAVI | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted / GSK, IAVI | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| PGDM1400 / National Institute of Allergy and Infectious Diseases, IAVI | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| mRNA-1644 / Moderna | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| 10-1074-LS-J / IAVI, Rockefeller University | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| 10E8.4/iMab / Bill & Melinda Gates Foundation, IAVI, TaiMed Biologics | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| 3BNC117-LS-J / Rockefeller University, IAVI | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| V590 / Merck (MSD), IAVI | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| mRNA-1644v2-Core / Moderna, IAVI | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
|
